Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with Rituximab and Bendamustine in CD30+ DLBCL
NCT02594163Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Seagen Inc.. Started Oct 2015; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02594163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594163.